PT Kalbe Farma Tbk (KLBF) Q2 2026 earnings summary

Executive summary

• Net sales for the first half of 2026 reached Rp19.48 trillion, up 14.1% year-over-year from Rp17.08 trillion in the same period of 2025.

• Net income attributable to owners was Rp1.92 trillion, a decrease from Rp1.97 trillion year-over-year.

• Total assets increased to Rp33.08 trillion as of June 30, 2026, from Rp30.70 trillion at year-end 2025.

• The group maintained a strong cash position with cash and cash equivalents of Rp4.83 trillion.

Financial highlights

• Gross profit rose to Rp7.32 trillion from Rp7.00 trillion year-over-year.

• Operating income before tax was Rp2.53 trillion, slightly down from Rp2.61 trillion year-over-year.

• Basic earnings per share was Rp42.42, compared to Rp43.35 in the prior year.

• Total equity increased to Rp25.76 trillion from Rp24.73 trillion at year-end 2025.

• Cash flow from operations was Rp1.25 trillion, nearly flat year-over-year.

Outlook and guidance

• Management continues to monitor geopolitical risks and macroeconomic volatility, especially in Myanmar and the Middle East, which may indirectly impact operations.

• No direct operations in conflict zones, but global supply chain and commodity price volatility are being closely watched.